fda compounding semaglutide crackdown 2025 news 🚨 Moves to Shut Down Mass-Market Compounded GLP-1s The FDA is taking action to restrict widely marketed, non–FDA-approved compounded GLP-1 products, citing concerns over safety, quality, and misleading claims. As demand FDA to Restrict Ingredients Used

The high price of brand-name GLP-1 medications is one of the biggest challenges for patients seeking obesity treatment (BMI 30 or more), overweight (BMI 27 or more), and type 2 diabetes mellitus

Emerging research suggests these medications may offer unexpected mental health benefits, with observational studies indicating potential reductions in depression symptoms among users

Limit liquid sugar and fructose-heavy inputs , this is a common lever on hepatic de novo lipogenesis

DEFINITION 03 Lyophilized Freeze-dried

All medically necessary items are permitted

Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system